CVE-2023-26979

CVE-2023-26979 is a low-severity vulnerability in Bluetens Bluetensq with a CVSS 3.x base score of 3.1. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-924.

Key facts

Description

Bluetens Electrostimulation Device BluetensQ device app version 4.3.15 is vulnerable to Man-in-the-middle attacks in the BLE channel. It allows attackers to decrease or increase the intensity of the stimulator by hijacking the BLE communication.

Frequently asked questions

What is CVE-2023-26979?
Bluetens Electrostimulation Device BluetensQ device app version 4.3.15 is vulnerable to Man-in-the-middle attacks in the BLE channel. It allows attackers to decrease or increase the intensity of the stimulator by hijacking the BLE communication.
How severe is CVE-2023-26979?
CVE-2023-26979 has a CVSS 3.x base score of 3.1, rated low severity. It is exploitable over an adjacent network with high attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity low, and availability none.
Is CVE-2023-26979 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (8th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-26979?
CVE-2023-26979 affects Bluetens Bluetensq. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-26979?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2023-26979 published?
CVE-2023-26979 was published on 2023-08-03 and last updated on 2026-07-09.

References

Affected products (1)

Other CWE-924 vulnerabilities

Browse all CWE-924 vulnerabilities →